Preview

Rational Pharmacotherapy in Cardiology

Advanced search

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE

https://doi.org/10.20996/1819-6446-2007-3-3-52-59

Full Text:

Abstract

The clinical, cell and genetic factors are distinguished among reasons for resistance to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have disadvantages. Moreover, there is no unified approach for interpretation of received results, and no recommendations for their practical use. It is necessary to work out unified procedure to assess platelet function, to define indications for its usage and to work out unified criteria of resistance. Individualized approach and each patient’s peculiarities consideration are essential when prescribing antiplatelet therapy.

About the Authors

D. H. Aynetdinova
Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Chair of Faculty therapy №1


A. E. Udovichenko
Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Chair of Faculty therapy №1


V. A. Sulimov
Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Chair of Faculty therapy №1


References

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81- 106.

2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.

3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;332:349-60.

4. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events. Lanset 1996;348: 1329-39.

5. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndroums without ST elevation. The CURE trial investigators. N Engl J Med 2001;345:494-502.

6. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.

7. Sabatine MS, Cannon CP, Gibson CM, et al, the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–89.

8. Chen Z, Jiang L, Chen Y, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.

9. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43:1127-29.

10. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311-6.

11. Fifth annual conference on Arteriosclerosis, Thrombosis and Vascular Biology: San Francisco, California, USA: 6-8 May 2004.

12. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.

13. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166–71.

14. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit plateletaggregation: a new drug-drug interaction. Circulation 2003;107:32-7.

15. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitoryeffects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003;24:1744-9.

16. Saw J, Steinhubl SR, Berger PB, et al. Clopidogrel for the Reduction of Events During ObservationInvestigators. Lack of adverse clopidogrel atorvastatin clinicalinteraction from secondary analysis of a randomized, placebocontrolledclopidogrel trial. Circulation 2003;108:921-4.

17. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7.

18. Serebruany VL, Malinin AI, Callahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001;159:239–41.

19. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4.

20. Gorchakova O, von Beckerath N, Gawaz MЮ, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-902.

21. Serebruany VL, Malinin AI, Jerome SD, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the plavix use for treatment of congestive heart failure (PLUTO-CHF) trial. Am Heart J 2003;146:713-20.

22. Hobikoglu GF, Norgaz T, Aksu H, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med. 2005;207(1):59-64.

23. Rasmanis G, Vesterqvist O, Green K, et al. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet 1988, 2(8605): 245-7.

24. Heper G, Bayraktaroglu M. The importance of von Willebrand factor level and heart rate changes in acute coronary syndromes: a comparison with chronic ischemic onditions. Angiology 2003;54:287-99.

25. Malhotra S, Sharma YP, Grover A, et al. Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Intern Med J 2003;33:350-4.

26. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J 1986;233:309-19.

27. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 2002;66:557-8.

28. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996;16:948-54.

29. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999;33:1286-93.

30. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin is reduced in patients with hyperlipidaemia. BMJ 2003;326:82-3.

31. Christiaens L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery dis￾ease. Thromb Res 2003;108:115–9.

32. Weber AA, Zimmerman KC, Meyer-Kirchrath J, et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.

33. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-7.

34. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008-14.

35. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-37.

36. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T kozak (GP Ib [alpha]) polymorphisms. J Am Coll Cardiol 2003;42:1115-9.

37. Undas A, Brummel K, Musial J, et al. Pl(A2) Polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666- 72.

38. Pontiggia L, Lassila R, Pederiva S, et al. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa. Arterioscler Thromb Vasc Biol 2002;22:2093-8.

39. Quinn M, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2001;2:341-52.

40. Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol 2005;95:805-8.

41. Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2 Haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003;108:2971-3.

42. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989–95.

43. von Beckerath N, von Beckerath O, Koch W, et al. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005;16:199-204.

44. Gum PA, Kottke-Marchant K, Welsh PA, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.

45. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999;99: 620–5.

46. Stejskal D, Proskova J, Petrzelova A, et al. Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluation of effectiveness of antiaggregation therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001;145:69-74.

47. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. Am J Cardiol 2003;92:1492-4.

48. Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986;83:5861–5865.

49. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.

50. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005;51(6):957-65.

51. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-13.

52. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89: 783-7.

53. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430-5.

54. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15-28.

55. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118(7):723-7.

56. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.

57. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.

58. Klamroth R, Hoffmann S, Andresen D, Landgraf H. Clopidogrel resistance and aspirin resistance - a cause of coronary artery stent thrombosis? American Society of Hematology 2004 104: Abstract 4070.

59. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 study. Circulation 2005;111:1-8.

60. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900- mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-50.

61. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-73.

62. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13:407-13.

63. Asfour AI, Greenbaum AB, McFarland TM, et al. Facilitated angioplasty with combined ADP P2T receptor blockade and fibrinolysis for the treatment of acute myocardial infarction: results from the STEP-AMI trial. J Am Coll Cardiol 2002;39:39.

64. Greenbaum AB, Ohman EM, Gibson MS, et al. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction. J Am Coll Cardiol 2002;39:281.

65. Cannon C, Husted S, Storey R, et al. for the DISPERSE 2 Investigators. The DISPERSE2 Trial: Safety, Tolerability and Preliminary Efficacy of AZD6140, the First Oral Reversible ADP Receptor Antagonist, Compared with Clopidogrel in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. In: American Heart Association Scientific Sessions. Dallas, TX: 2005.

66. Fox KA, Cokkinos DV, Deckers J, et al. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 2000;21:1440-9.

67. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebocontrolled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399-406.


For citation:


Aynetdinova D.H., Udovichenko A.E., Sulimov V.A. RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2007;3(3):52-59. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-3-52-59

Views: 381


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)